Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (NASDAQ: TRVI) reported that it completed an End-of-Phase 2 meeting with the FDA and gained alignment on its development plan for Haduvio (oral nalbuphine ER) in IPF-related chronic cough. Two pivotal Phase 3 trials will run in parallel, with initiation targeted in Q2 2026 and the second in H2 2026. The program also includes remaining Phase 1 studies the company expects to complete to support an NDA.
Both randomized, double-blind, placebo-controlled global trials will test 54 mg BID dosing, use objective 24-hour cough-frequency as the primary endpoint, and randomize patients 2:1 versus placebo.
Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in two March 2026 industry events: the Leerink Partners 2026 Global Healthcare Conference in Miami and the Access USA Rare Disease Summit in Philadelphia.
Presentations include a March 11 fireside chat with Jennifer Good and James Cassella and a March 18 panel session featuring Farrell Simon. A live webcast link is provided for the Leerink fireside chat.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 9:20 a.m. ET.
Jennifer Good, President and CEO, and David Hastings, CFO, will speak and hold investor meetings during the virtual conference Feb 25–26. Trevi is a clinical-stage biopharmaceutical developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.
Trevi Therapeutics (Nasdaq: TRVI) announced that key Phase 2b CORAL trial results for oral nalbuphine ER in idiopathic pulmonary fibrosis (IPF) chronic cough were published in JAMA on Jan 22, 2026. The trial showed a statistically significant reduction in 24-hour objective cough frequency across all dose groups at Week 6, with significant effects as early as Week 2. More than 60% of treated patients achieved ≥50% reduction in 24-hour cough frequency at Week 6. Patient-reported outcomes aligned with objective monitoring. Safety was consistent with prior data; discontinuations due to adverse events were 6% in treated groups versus 5% for placebo.
Getty Realty (NYSE: GTY) announced the 2025 dividend tax allocations for its common stock (CUSIP 374297109) as they will appear on Form 1099-DIV.
The company reported total 2025 distributions of $1.880000 per share, comprised of ordinary income $1.085936, capital gains $0.050080 (including unrecaptured Sec 1250 of $0.009692) and non-dividend distributions $0.743984. Dividends were paid quarterly with record dates 12/26/2024, 3/27/2025, 6/26/2025 and 9/25/2025 and payable dates 1/9/2025, 4/10/2025, 7/10/2025 and 10/9/2025.
A tax disclaimer advised shareholders to consult their tax advisors for specific federal, state and local tax consequences. As of 12/31/2025, Getty reported a portfolio of 1,174 properties in 44 states and Washington, D.C.
Trevi Therapeutics (Nasdaq: TRVI) provided strategic clinical updates ahead of the LifeSci Partners event (Jan 12-14, 2026) during J.P. Morgan week. The company has an FDA End-of-Phase 2 meeting scheduled in Q1 2026 for nalbuphine ER (Haduvio) for chronic cough in IPF and expects to initiate a Phase 3 program in IPF in H1 2026 following that meeting. Trevi also plans to start a Phase 2b trial in refractory chronic cough (RCC) in H1 2026. New CFO David Hastings will attend the LifeSci event with senior management.
Trevi Therapeutics (Nasdaq: TRVI) announced that David Hastings will become Chief Financial Officer effective January 6, 2026.
Mr. Hastings brings over 25 years of life‑science financial leadership, having raised more than $2B in equity and debt and held CFO roles at Arbutus, Unilife, Incyte, and ArQule. He served as CFO during Incyte's commercialization of Jakafi and co‑led out‑licensing negotiations; he currently chairs the audit committee at Scynexis.
Management says Hastings will help guide Trevi as it advances Haduvio (oral nalbuphine ER) into Phase 3 development for chronic cough in IPF, non‑IPF ILD, and RCC, citing statistically significant data, limited competition, and a strong cash position.
Trevi Therapeutics (Nasdaq: TRVI) reported third-quarter 2025 results and clinical updates on November 13, 2025. The company ended Q3 2025 with $194.9 million in cash, cash equivalents and marketable securities and expects a cash runway into 2028. Trevi plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and to initiate a Phase 3 IPF chronic cough program in H1 2026. A Phase 1 IPF safety study (TIDAL) sentinel cohort showed no safety signals; enrollment completion and study data are expected in Q4 2025. A Phase 1 drug-drug interaction study showed no clinically meaningful PK interactions with pirfenidone or nintedanib. Topline Phase 2b CORAL and Phase 2a RIVER results were presented at CHEST 2025 and ERS Congress 2025. Q3 2025 net loss was $11.8 million.
Trevi Therapeutics (Nasdaq: TRVI) announced a conference call and live audio webcast for Thursday, November 13, 2025 at 4:30 p.m. ET to provide a corporate update and review third quarter financial results for the period ended September 30, 2025.
Senior management will host the call; domestic dial-in is (877) 870 4263 and international dial-in is (412) 317 0790. No access code is required. A live audio webcast will be available from the Investors & News section at www.TreviTherapeutics.com, with an archived replay accessible on the company website for 30 days after the event.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in the Stifel 2025 Healthcare Conference in New York on November 11–12, 2025.
A fireside chat featuring Jennifer Good, President and CEO, and James Cassella, Ph.D., Chief Development Officer, is scheduled for Tuesday, November 11, 2025 at 3:20 p.m. ET. Company executives will also hold investor meetings with conference attendees. The fireside chat and meetings will be available for in-person attendees.